Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review

Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L)1 molecules, have shown impressive therapeutic results. Durable responses, however, are only observed in a segment of the patient population and must be offset against severe off-target immune toxicity and high costs. This calls for b...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Melanoma Res
Asıl Yazarlar: Ouwerkerk, Wouter, van den Berg, Mirjam, van der Niet, Sanne, Limpens, Jacqueline, Luiten, Rosalie M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2019
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727956/
https://ncbi.nlm.nih.gov/pubmed/30855527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000589
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller